Josephine Herz1, Pascal Sabellek2, Thomas E Lane2, Matthias Gunzer2, Dirk M Hermann2, Thorsten R Doeppner2. 1. From the Department of Neurology (J.H., P.S., D.M.H., T.R.D.), Department of Pediatrics I (J.H.), and Institute of Experimental Immunology and Imaging, University Duisburg-Essen (M.G.), University Hospital Essen, Essen, Germany; and Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City (T.E.L.). josephine.herz@uk-essen.de thorsten.doeppner@uk-essen.de. 2. From the Department of Neurology (J.H., P.S., D.M.H., T.R.D.), Department of Pediatrics I (J.H.), and Institute of Experimental Immunology and Imaging, University Duisburg-Essen (M.G.), University Hospital Essen, Essen, Germany; and Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City (T.E.L.).
Abstract
BACKGROUND AND PURPOSE: Inflammation-related comorbidities contribute to stroke-induced immune responses and brain damage. We previously showed that hyperlipidemia exacerbates ischemic brain injury, which is associated with elevated peripheral and cerebral granulocyte numbers. Herein, we evaluate the contribution of neutrophils to the exacerbation of ischemic brain injury. METHODS: Wild-type mice fed with a normal chow and ApoE knockout mice fed with a high cholesterol diet were exposed to middle cerebral artery occlusion. CXCR2 was blocked using the selective antagonist SB225002 (2 mg/kg) or neutralizing CXCR2 antiserum. Neutrophils were depleted using an anti-Ly6G antibody. At 72 hours post ischemia, immunohistochemistry, flow cytometry, and real-time polymerase chain reaction were performed to determine cerebral tissue injury and immunologic changes in the blood, bone marrow, and brain. Functional outcome was assessed by accelerated rota rod and tight rope tests at 4, 7, and 14 days post ischemia. RESULTS: CXCR2 antagonization reduced neurological deficits and infarct volumes that were exacerbated in hyperlipidemic ApoE-/- mice. This effect was mimicked by neutrophil depletion. Cerebral neutrophil infiltration and peripheral neutrophilia, which were increased on ischemia in hyperlipidemia, were attenuated by CXCR2 antagonization. This downscaling of neutrophil responses was associated with increased neutrophil apoptosis and reduced levels of CXCR2, inducible nitric oxide synthase, and NADPH oxidase 2 expression on bone marrow neutrophils. CONCLUSIONS: Our data demonstrate a role of neutrophils in the exacerbation of ischemic brain injury induced by hyperlipidemia. Accordingly, CXCR2 blockade, which prevents neutrophil recruitment into the brain, might be an effective option for stroke treatment in patients with hyperlipidemia.
BACKGROUND AND PURPOSE:Inflammation-related comorbidities contribute to stroke-induced immune responses and brain damage. We previously showed that hyperlipidemia exacerbates ischemic brain injury, which is associated with elevated peripheral and cerebral granulocyte numbers. Herein, we evaluate the contribution of neutrophils to the exacerbation of ischemic brain injury. METHODS: Wild-type mice fed with a normal chow and ApoE knockout mice fed with a high cholesterol diet were exposed to middle cerebral artery occlusion. CXCR2 was blocked using the selective antagonist SB225002 (2 mg/kg) or neutralizing CXCR2 antiserum. Neutrophils were depleted using an anti-Ly6G antibody. At 72 hours post ischemia, immunohistochemistry, flow cytometry, and real-time polymerase chain reaction were performed to determine cerebral tissue injury and immunologic changes in the blood, bone marrow, and brain. Functional outcome was assessed by accelerated rota rod and tight rope tests at 4, 7, and 14 days post ischemia. RESULTS:CXCR2 antagonization reduced neurological deficits and infarct volumes that were exacerbated in hyperlipidemic ApoE-/- mice. This effect was mimicked by neutrophil depletion. Cerebral neutrophil infiltration and peripheral neutrophilia, which were increased on ischemia in hyperlipidemia, were attenuated by CXCR2 antagonization. This downscaling of neutrophil responses was associated with increased neutrophil apoptosis and reduced levels of CXCR2, inducible nitric oxide synthase, and NADPH oxidase 2 expression on bone marrow neutrophils. CONCLUSIONS: Our data demonstrate a role of neutrophils in the exacerbation of ischemic brain injury induced by hyperlipidemia. Accordingly, CXCR2 blockade, which prevents neutrophil recruitment into the brain, might be an effective option for stroke treatment in patients with hyperlipidemia.
Authors: Yuqing Huo; Andreas Schober; S Bradley Forlow; David F Smith; Matthew Craig Hyman; Steffen Jung; Dan R Littman; Christian Weber; Klaus Ley Journal: Nat Med Date: 2002-12-16 Impact factor: 53.440
Authors: Anja Köhler; Katia De Filippo; Mike Hasenberg; Cindy van den Brandt; Emma Nye; Martin P Hosking; Thomas E Lane; Linda Männ; Richard M Ransohoff; Anja E Hauser; Oliver Winter; Burkhart Schraven; Hartmut Geiger; Nancy Hogg; Matthias Gunzer Journal: Blood Date: 2011-01-11 Impact factor: 22.113
Authors: Vanessa H Brait; Jennifer Rivera; Brad R S Broughton; Seyoung Lee; Grant R Drummond; Christopher G Sobey Journal: Brain Res Date: 2010-12-04 Impact factor: 3.252
Authors: Maik Drechsler; Remco T A Megens; Marc van Zandvoort; Christian Weber; Oliver Soehnlein Journal: Circulation Date: 2010-10-18 Impact factor: 29.690
Authors: Josephine Herz; Raluca Reitmeir; Sabine I Hagen; Barbara S Reinboth; Zeyun Guo; Anil Zechariah; Ayman ElAli; Thorsten R Doeppner; Marco Bacigaluppi; Stefano Pluchino; Ulkan Kilic; Ertugrul Kilic; Dirk M Hermann Journal: Neurobiol Dis Date: 2011-12-17 Impact factor: 5.996
Authors: Ryan A Frieler; Yutein Chung; Carolyn G Ahlers; George Gheordunescu; Jianrui Song; Thomas M Vigil; Yatrik M Shah; Richard M Mortensen Journal: Exp Neurol Date: 2017-08-31 Impact factor: 5.330
Authors: Andrew J Bryant; Vinayak Shenoy; Chunhua Fu; George Marek; Kyle J Lorentsen; Erica L Herzog; Mark L Brantly; Dorina Avram; Edward W Scott Journal: Am J Respir Cell Mol Biol Date: 2018-02 Impact factor: 6.914
Authors: Daniela Michlmayr; Susana V Bardina; Carlos A Rodriguez; Alexander G Pletnev; Jean K Lim Journal: J Immunol Date: 2016-04-29 Impact factor: 5.422